ATXI:NSD-Avenue Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 11.31

Change

0.00 (0.00)%

Market Cap

USD 0.19B

Volume

0.04M

Average Target Price

USD 13.00 (+14.94%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.58 (+1.36%)

USD68.76B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

+15.81 (+2.85%)

USD59.12B 21.90 16.92
SGEN Seattle Genetics, Inc

+3.12 (+1.74%)

USD31.48B N/A N/A
MRNA Moderna, Inc

-0.54 (-0.78%)

USD27.33B N/A N/A
GMAB Genmab A/S

-0.35 (-0.91%)

USD25.18B 27.12 3.06
BGNE BeiGene, Ltd

-2.27 (-0.84%)

USD25.05B N/A N/A
RPRX Royalty Pharma plc

+1.13 (+2.78%)

USD24.64B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

+2.77 (+2.48%)

USD24.49B 30.43 27.52
IMMU Immunomedics, Inc

-0.36 (-0.42%)

USD19.70B N/A N/A
INCY Incyte Corporation

+1.54 (+1.80%)

USD18.67B 47.64 35.20

ETFs Containing ATXI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.81% 65% D 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.81% 65% D 75% C
Trailing 12 Months  
Capital Gain 85.41% 79% C+ 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 85.41% 79% C+ 89% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 27.25% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.25% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.74% N/A N/A N/A N/A
Risk Adjusted Return 63.76% N/A N/A N/A N/A
Market Capitalization 0.19B 40% F 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 45.45 2% F 2% F
Price / Cash Flow Ratio -7.16 57% F 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -119.82% 25% F 10% F
Return on Invested Capital -851.52% 1% F 0% N/A
Return on Assets -65.30% 8% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.68 47% F 36% F
Short Percent 6.05% 51% F 34% F
Beta 0.20 93% A 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector